Department of Urology, West China Hospital of Medicine, Chengdu, China.
Department of Urology, Hospital of Chengdu University, Chengdu, China.
Int Urol Nephrol. 2023 Nov;55(11):2829-2844. doi: 10.1007/s11255-023-03570-9. Epub 2023 Apr 5.
Intravenous fluid therapy is important for pediatric and adult patients in intensive care units (ICUs). However, medical professionals continue to struggle to determine the most appropriate fluids to obtain the best possible outcomes for each patient.
We conducted a meta-analysis involving cohort studies and randomized controlled trials (RCTs) to compare the influence of balanced crystalloid solutions and normal saline among patients in ICUs.
Studies that compared balanced crystalloid solutions and saline in ICU patients from databases including PubMed, Embase, Web of Science, and Cochrane Library were systematically searched up to July 25, 2022. The primary outcomes were mortality and renal-related outcomes, which included major adverse kidney events within 30 days (MAKE30), acute kidney injury (AKI), new receipt of renal replacement therapy (RRT), maximum creatinine increasing, maximum creatinine level, and final creatinine level ≥ 200% of baseline. Service utilization including length of hospital stay, ICU stay, ICU-free days and ventilator-free days were also reported.
A total of 13 studies (10 RCTs and 3 cohort studies) involving 38,798 patients in ICUs met the selection criteria. Our analysis revealed that each subgroup had no significant difference in mortality outcomes among ICU patients between balanced crystalloid solutions and normal saline. A significant difference was detected between the adult groups (odds ratio [OR], 0.92; 95% confidence interval [CI], [0.86, 1.00]; p = 0.04) indicating that the AKI in the balanced crystalloid solutions group was lower than that in the normal saline group. Other renal-related outcomes, such as MAKE30, RRT, maximum creatinine increasing, maximum creatinine level, and final creatinine level ≥ 200% of baseline showed no significant difference between the two groups. Regarding secondary outcomes, the balanced crystalloid solution group had a longer ICU stay time (WMD, 0.02; 95% CI, [0.01, 0.03]; p = 0.0004 and I = 0%; p = 0.96) than the normal saline group among adult patients. Furthermore, children treated with balanced crystalloid solution had a shorter hospital stay time (WMD, - 1.10; 95% CI, [- 2.10, - 0.10]; p = 0.03 and I = 17%; p = 0.30) than those treated with saline.
Compared with saline, balanced crystalloid solutions could not reduce the risk of mortality and renal-related outcomes, including MAKE30, RRT, maximum creatinine increasing, maximum creatinine level, and final creatinine level ≥ 200% of baseline, but the solutions may reduce total AKI incidence among adult patients in ICUs. For service utilization outcomes, balanced crystalloid solutions were associated with a longer length of ICU stay in the adult group and shorter length of hospital stay in the pediatric group.
静脉补液治疗对于重症监护病房(ICU)中的儿科和成年患者非常重要。然而,医疗专业人员在确定最适合的液体以获得每个患者最佳结果方面仍存在困难。
我们进行了一项荟萃分析,纳入了队列研究和随机对照试验(RCT),以比较 ICU 患者中平衡晶体溶液和生理盐水的影响。
系统检索了包括 PubMed、Embase、Web of Science 和 Cochrane 图书馆在内的数据库中比较 ICU 患者中平衡晶体溶液和生理盐水的研究。主要结局是死亡率和肾脏相关结局,包括 30 天内主要不良肾脏事件(MAKE30)、急性肾损伤(AKI)、新接受肾脏替代治疗(RRT)、最大肌酐增加、最大肌酐水平和最终肌酐水平≥基线的 200%。还报告了服务利用情况,包括住院时间、ICU 停留时间、ICU 无天数和呼吸机无天数。
共有 13 项研究(10 项 RCT 和 3 项队列研究)符合纳入标准,涉及 38798 名 ICU 患者。我们的分析表明,平衡晶体溶液和生理盐水组 ICU 患者的死亡率结局无显著差异。在成年组中检测到显著差异(比值比[OR],0.92;95%置信区间[CI],[0.86,1.00];p=0.04),表明平衡晶体溶液组的 AKI 低于生理盐水组。其他肾脏相关结局,如 MAKE30、RRT、最大肌酐增加、最大肌酐水平和最终肌酐水平≥基线 200%,两组间无显著差异。关于次要结局,平衡晶体溶液组成年患者的 ICU 停留时间更长(WMD,0.02;95%CI,[0.01,0.03];p=0.0004,I=0%;p=0.96)。此外,接受平衡晶体溶液治疗的儿童的住院时间更短(WMD,-1.10;95%CI,[-2.10,-0.10];p=0.03,I=17%;p=0.30)。
与生理盐水相比,平衡晶体溶液不能降低死亡率和肾脏相关结局(包括 MAKE30、RRT、最大肌酐增加、最大肌酐水平和最终肌酐水平≥基线 200%)的风险,但可能降低 ICU 成年患者总 AKI 的发生率。在服务利用结局方面,平衡晶体溶液与成年组 ICU 停留时间延长和儿科组住院时间缩短有关。